David N. Boone, Ph.D. - Related publications

Affiliations: 
2011 Vanderbilt University, Nashville, TN 
Area:
Cell Biology, Molecular Biology
NOTE: We are testing a new system for identifying relevant work based on semantic analysis that identifies similarities between recently published papers and the current author's publications. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches.
50 most relevant papers in past 60 days:
Year Citation  Score
2021 Tokheim C, Wang X, Timms RT, Zhang B, Mena EL, Wang B, Chen C, Ge J, Chu J, Zhang W, Elledge SJ, Brown M, Liu XS. Systematic characterization of mutations altering protein degradation in human cancers. Molecular Cell. PMID 33567269 DOI: 10.1016/j.molcel.2021.01.020   
2021 Boutelle AM, Attardi LD. p53 and Tumor Suppression: It Takes a Network. Trends in Cell Biology. PMID 33518400 DOI: 10.1016/j.tcb.2020.12.011   
2021 Ng ZL, Siew J, Li J, Ji G, Huang M, Liao X, Yu S, Chew Y, Png CW, Zhang Y, Wen S, Yang H, Zhou Y, Long YC, Jiang ZH, et al. PATZ1 (MAZR) Co-occupies Genomic Sites With p53 and Inhibits Liver Cancer Cell Proliferation via Regulating p27. Frontiers in Cell and Developmental Biology. 9: 586150. PMID 33598459 DOI: 10.3389/fcell.2021.586150   
2021 Dey N, Aske J, De P. Targeted Neoadjuvant Therapies in HR+/HER2-Breast Cancers: Challenges for Improving pCR. Cancers. 13. PMID 33530335 DOI: 10.3390/cancers13030458   
2021 Bhat S, Kabekkodu SP, Adiga D, Fernandes R, Shukla V, Bhandari P, Pandey D, Sharan K, Satyamoorthy K. ZNF471 modulates EMT and functions as methylation regulated tumor suppressor with diagnostic and prognostic significance in cervical cancer. Cell Biology and Toxicology. PMID 33566221 DOI: 10.1007/s10565-021-09582-4   
2021 Singh S, Sutcliffe MD, Repich K, Atkins KA, Harvey JA, Janes KA. Pan-cancer Drivers are Recurrent Transcriptional Regulatory Heterogeneities in Early-stage Luminal Breast Cancer. Cancer Research. PMID 33531373 DOI: 10.1158/0008-5472.CAN-20-1034   
2021 Shen W, Zhang X, Tang J, Zhang Z, Du R, Luo D, Liu X, Xia Y, Li Y, Wang S, Yan S, Yang W, Xiang R, Luo N, Luo Y, et al. CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis. Theranostics. 11: 2297-2317. PMID 33500726 DOI: 10.7150/thno.51000   
2021 Khan MI, Zamzami MA, Ahmad A, Choudhry H. Molecular profiling of epigenetic landscape of cancer cells during extracellular matrix detachment. Scientific Reports. 11: 2784. PMID 33531586 DOI: 10.1038/s41598-021-82431-w   
2021 Garcia-Escolano M, Montoyo-Pujol YG, Ortiz-Martinez F, Ponce JJ, Delgado-Garcia S, Martin TA, Ballester H, Aranda FI, Castellon-Molla E, Sempere-Ortells JM, Peiro G. ID1 and ID4 Are Biomarkers of Tumor Aggressiveness and Poor Outcome in Immunophenotypes of Breast Cancer. Cancers. 13. PMID 33514024 DOI: 10.3390/cancers13030492   
2021 Zhou J, Zhang S, Luo M. LncRNA promotes the malignant progression of breast cancer by regulating ErbB/PI3K/Akt pathway. Future Oncology (London, England). PMID 33401925 DOI: 10.2217/fon-2020-0273   
2021 Li Y, Cui K, Zhang Q, Li X, Lin X, Tang Y, Prochownik EV, Li Y. FBXL6 degrades phosphorylated p53 to promote tumor growth. Cell Death and Differentiation. PMID 33568778 DOI: 10.1038/s41418-021-00739-6   
2021 Song JH, Park J, Park SL, Hwang B, Kim WJ, Lee C, Moon SK. A Novel Cyclic Pentadepsipeptide, -Methylsansalvamide, Suppresses Angiogenic Responses and Exhibits Antitumor Efficacy against Bladder Cancer. Cancers. 13. PMID 33430488 DOI: 10.3390/cancers13020191   
2021 Dhimolea E, de Matos Simoes R, Kansara D, Al'Khafaji A, Bouyssou J, Weng X, Sharma S, Raja J, Awate P, Shirasaki R, Tang H, Glassner BJ, Liu Z, Gao D, Bryan J, et al. An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. Cancer Cell. PMID 33417832 DOI: 10.1016/j.ccell.2020.12.002   
2021 Liu Y, Guo W. SOX factors as cell-state regulators in the mammary gland and breast cancer. Seminars in Cell & Developmental Biology. PMID 33583737 DOI: 10.1016/j.semcdb.2021.01.002   
2021 Pan YC, Nishikawa T, Chang CY, Tai JA, Kaneda Y. CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy. Molecular Therapy Oncolytics. 20: 175-186. PMID 33575480 DOI: 10.1016/j.omto.2020.12.011   
2021 Thomas PB, Jeffery P, Gahete MD, Whiteside E, Walpole C, Maugham M, Jovanovic L, Gunter J, Williams E, Nelson C, Herington A, Luque RM, Veedu R, Chopin LK, Seim I. The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype. Peerj. 9: e10280. PMID 33585078 DOI: 10.7717/peerj.10280   
2021 Jian Y, Huang X, Fang L, Wang M, Liu Q, Xu H, Kong L, Chen X, Ouyang Y, Wang X, Wei W, Song L. Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer. Journal of Experimental & Clinical Cancer Research : Cr. 40: 56. PMID 33541412 DOI: 10.1186/s13046-021-01856-3   
2021 Wijshake T, Zou Z, Chen B, Zhong L, Xiao G, Xie Y, Doench JG, Bennett L, Levine B. Tumor-suppressor function of Beclin 1 in breast cancer cells requires E-cadherin. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33495338 DOI: 10.1073/pnas.2020478118   
2021 Gao W, Wen H, Liang L, Dong X, Du R, Zhou W, Zhang X, Zhang C, Xiang R, Li N. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer. Theranostics. 11: 2564-2580. PMID 33456560 DOI: 10.7150/thno.45280   
2021 Lawal B, Liu YL, Mokgautsi N, Khedkar H, Sumitra MR, Wu ATH, Huang HS. Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines. Biomedicines. 9. PMID 33477856 DOI: 10.3390/biomedicines9010092   
2021 Monteverde T, Sahoo S, La Montagna M, Magee P, Shi L, Lee D, Sellers R, Baker AR, Leong HS, Fassan M, Garofalo M. CKAP2L promotes non-small cell lung cancer progression through regulation of transcription elongation. Cancer Research. PMID 33472893 DOI: 10.1158/0008-5472.CAN-20-1968   
2021 Shibasaki H, Kinoh H, Cabral H, Quader S, Mochida Y, Liu X, Toh K, Miyano K, Matsumoto Y, Yamasoba T, Kataoka K. Efficacy of pH-Sensitive Nanomedicines in Tumors with Different c-MYC Expression Depends on the Intratumoral Activation Profile. Acs Nano. PMID 33625824 DOI: 10.1021/acsnano.1c00364   
2021 An CX, Xie SP, Li HL, Hu YH, Niu R, Zhang LJ, Jiang Y, Li Q, Zhou YN. Knockdown of Microtubule Associated Serine/threonine Kinase Like Expression Inhibits Gastric Cancer Cell Growth and Induces Apoptosis by Activation of ERK1/2 and Inactivation of NF-κB Signaling. Current Medical Science. 41: 108-117. PMID 33582914 DOI: 10.1007/s11596-021-2325-2   
2021 Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, Qin S, Zhang L, Ouyang H, Du P, Jiang L, Zhang B, Yang Y, Wang X, Ren X, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 184: 792-809.e23. PMID 33545035 DOI: 10.1016/j.cell.2021.01.010   
2021 Lu Y, Zhu Y, Deng S, Chen Y, Li W, Sun J, Xu X. Targeting the Sonic Hedgehog Pathway to Suppress the Expression of the Cancer Stem Cell (CSC)-Related Transcription Factors and CSC-Driven Thyroid Tumor Growth. Cancers. 13. PMID 33499351 DOI: 10.3390/cancers13030418   
2021 Butti R, Nimma R, Kundu G, Bulbule A, Kumar TVS, Gunasekaran VP, Tomar D, Kumar D, Mane A, Gill SS, Patil T, Weber GF, Kundu GC. Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression. Oncogene. PMID 33603163 DOI: 10.1038/s41388-021-01663-2   
2021 Wu Z, Ding Z, Cheng B, Cui Z. The inhibitory Effect of human DEFA5 in Growth of gastric cancer by targeting BMI-1. Cancer Science. PMID 33503272 DOI: 10.1111/cas.14827   
2021 Ashrafizadeh M, Gholami MH, Mirzaei S, Zabolian A, Haddadi A, Farahani MV, Kashani SH, Hushmandi K, Najafi M, Zarrabi A, Ahn KS, Khan H. Dual relationship between long non-coding RNAs and STAT3 signaling in different cancers: New insight to proliferation and metastasis. Life Sciences. 119006. PMID 33421521 DOI: 10.1016/j.lfs.2020.119006   
2021 Xue C, Chen C, Gu X, Li L. Progress and assessment of lncRNA DGCR5 in malignant phenotype and immune infiltration of human cancers. American Journal of Cancer Research. 11: 1-13. PMID 33520356   
2021 Yang T, Wang P, Yin X, Zhang J, Huo M, Gao J, Li G, Teng X, Yu H, Huang W, Wang Y. The histone deacetylase inhibitor PCI-24781 impairs calcium influx and inhibits proliferation and metastasis in breast cancer. Theranostics. 11: 2058-2076. PMID 33500709 DOI: 10.7150/thno.48314   
2021 Zhang R, Tang L, Zhao B, Tian Y, Zhou B, Mu Y, Yang L. A Peptide-Based Small RNA Delivery System to Suppress Tumor Growth by Remodeling the Tumor Microenvironment. Molecular Pharmaceutics. PMID 33522823 DOI: 10.1021/acs.molpharmaceut.0c01253   
2021 Wei L, Ling M, Yang S, Xie Y, Liu C, Yi W. Long noncoding RNA NBAT1 suppresses hepatocellular carcinoma progression via competitively associating with IGF2BP1 and decreasing c-Myc expression. Human Cell. PMID 33387362 DOI: 10.1007/s13577-020-00464-1   
2021 Gao Y, Chen MK, Chu YY, Yang L, Yu D, Liu Y, Hung MC. Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells. American Journal of Cancer Research. 11: 236-250. PMID 33520371   
2021 Gao Y, Chen MK, Chu YY, Yang L, Yu D, Liu Y, Hung MC. Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells. American Journal of Cancer Research. 11: 236-250. PMID 33520371   
2021 Butler DSC, Cafaro C, Putze J, Wan MLY, Tran TH, Ambite I, Ahmadi S, Kjellström S, Welinder C, Chao SM, Dobrindt U, Svanborg C. A bacterial protease depletes c-MYC and increases survival in mouse models of bladder and colon cancer. Nature Biotechnology. PMID 33574609 DOI: 10.1038/s41587-020-00805-3   
2021 Hegde M, Joshi MB. Comprehensive analysis of regulation of DNA methyltransferase isoforms in human breast tumors. Journal of Cancer Research and Clinical Oncology. PMID 33604794 DOI: 10.1007/s00432-021-03519-4   
2021 Zhang M, Wei Z, Gong X, Li X, Kang S, Wang J, Liu B, Huang ZS, Li D. Syntheses and evaluation of acridone-naphthalimide derivatives for regulating oncogene PDGFR-β expression. Bioorganic & Medicinal Chemistry. 34: 116042. PMID 33561716 DOI: 10.1016/j.bmc.2021.116042   
2021 Wang K, Chen Q, Shao Y, Yin S, Liu C, Liu Y, Wang R, Wang T, Qiu Y, Yu H. Anticancer activities of TCM and their active components against tumor metastasis. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 133: 111044. PMID 33378952 DOI: 10.1016/j.biopha.2020.111044   
2021 Jinka S, Rachamalla HK, Bhattacharyya T, Sridharan K, Sekhar Jaggarapu MMC, Yakati V, Banerjee R. Glucocorticoid receptor-targeted liposomal delivery system for delivering small molecule ESC8 and anti-miR-Hsp90 gene construct to combat colon cancer. Biomedical Materials (Bristol, England). PMID 33434900 DOI: 10.1088/1748-605X/abdb08   
2021 Saunders AS, Bender DE, Ray AL, Wu X, Morris KT. Colony-stimulating factor 3 signaling in colon and rectal cancers: Immune response and CMS classification in TCGA data. Plos One. 16: e0247233. PMID 33606788 DOI: 10.1371/journal.pone.0247233   
2021 Qin J, Qu S, Zhu K, Cheng Y, Pan G, Jing W, Liu X, Sun X, Liu L. Rational design and synthesis of 6-aryl-6H-benzo[c]chromenes as non-steroidal progesterone receptor antagonists for use against cancers. Bioorganic & Medicinal Chemistry. 32: 116003. PMID 33461148 DOI: 10.1016/j.bmc.2021.116003   
2021 Gu X, Zheng Q, Chu Q, Zhu H. HAND2-AS1: A functional cancer-related long non-coding RNA. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 137: 111317. PMID 33556872 DOI: 10.1016/j.biopha.2021.111317   
2021 Bourn JR, Ruiz-Torres SJ, Hunt BG, Benight NM, Waltz SE. Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling. Cancer Letters. 503: 75-90. PMID 33508385 DOI: 10.1016/j.canlet.2021.01.019   
2021 Liu Y, Song H, Zhou Y, Ma X, Xu J, Yu Z, Chen L. The oncogenic role of protein kinase D3 in cancer. Journal of Cancer. 12: 735-739. PMID 33403031 DOI: 10.7150/jca.50899   
2021 Aziz MA, Sarwar MS, Akter T, Uddin MS, Xun S, Zhu Y, Islam MS, Hongjie Z. Polyphenolic molecules targeting signal transducer and activator of transcription 3 pathway for the treatment of cancer. Life Sciences. 118999. PMID 33421525 DOI: 10.1016/j.lfs.2020.118999   
2021 Li Y, Sun Y, Kulke M, Hechler T, Van der Jeught K, Dong T, He B, Miller KD, Radovich M, Schneider BP, Pahl A, Zhang X, Lu X. Targeted immunotherapy for HER2-low breast cancer with 17p loss. Science Translational Medicine. 13. PMID 33568521 DOI: 10.1126/scitranslmed.abc6894   
2021 Liu BB, Ma T, Sun W, Gao WY, Liu JM, Li LQ, Li WY, Wang S, Guo YY. Centromere protein U enhances the progression of bladder cancer by promoting mitochondrial ribosomal protein s28 expression. The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology. 25: 119-129. PMID 33602882 DOI: 10.4196/kjpp.2021.25.2.119   
2021 Steurer S, Riemann C, Büscheck F, Luebke AM, Kluth M, Hube-Magg C, Hinsch A, Höflmayer D, Weidemann S, Fraune C, Möller K, Menz A, Fisch M, Rink M, Bernreuther C, et al. p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. Biomarker Research. 9: 7. PMID 33494829 DOI: 10.1186/s40364-021-00260-5   
2021 Tottone L, Lancho O, Loh JW, Singh A, Kimura S, Roels J, Kuchmiy A, Strubbe S, Lawlor MA, da Silva-Diz V, Luo S, Gachet S, García-Prieto CA, Hagelaar R, Esteller M, et al. A Tumor Suppressor Enhancer of in T-cell development and leukemia. Blood Cancer Discovery. 2: 92-109. PMID 33458694 DOI: 10.1158/2643-3230.BCD-20-0201   
2021 Nishibeppu K, Komatsu S, Kiuchi J, Kishimoto T, Takashima Y, Shoda K, Arita T, Kosuga T, Konishi H, Shiozaki A, Kubota T, Okamoto K, Fujiwara H, Tsuda H, Otsuji E. TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer. Journal of Cancer. 12: 316-325. PMID 33391428 DOI: 10.7150/jca.47577